Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

31.63USD
2 Dec 2016
Change (% chg)

-- (--)
Prev Close
$31.63
Open
--
Day's High
--
Day's Low
--
Volume
1,416
Avg. Vol
23,280,214
52-wk High
$37.39
52-wk Low
$28.25

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company's segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $191,578.00
Shares Outstanding(Mil.): 6,068.35
Dividend: 0.30
Yield (%): 3.80

Financials

  PFE Industry Sector
P/E (TTM): 31.52 29.13 29.87
EPS (TTM): 1.00 -- --
ROI: 4.34 15.56 14.95
ROE: 9.51 16.69 16.29

Pfizer's Herceptin biosimilar succeeds in key breast cancer study

Pfizer Inc said on Wednesday its experimental biosimilar of Roche Holding AG's blockbuster breast cancer treatment Herceptin was found comparable with the branded version in a key study.

Nov 30 2016

BRIEF-FDA accepts the Biologics' license application for Avelumab for priority review

* FDA accepts the biologics license application for Avelumab for the treatment of metastatic merkel cell carcinoma for priority review

Nov 29 2016

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

German Merck, Pfizer get FDA priority review for cancer drug

FRANKFURT, Nov 29 German drugmaker Merck KGaA and U.S. partner Pfizer have been granted priority review status in the United States as they seek approval to fight a rare and aggressive form of skin cancer with immunotherapy drug avelumab.

Nov 29 2016

French cancer specialist Innate Pharma can remain independent, for now: CEO

PARIS France's Innate Pharma believes that its cash position and portfolio are sufficiently robust for the cancer drug company to remain independent for the time being and will seek co-development deals modeled on an agreement struck with AstraZeneca in April.

Nov 25 2016

BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe

* Quintilesims forms new collaboration with Bristol-Myers Squibb, Lilly, Merck Kgaa, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe Source text for Eikon: Further company coverage:

Nov 22 2016

Pfizer sues Texas health agency for releasing confidential information

Pfizer Inc has sued Texas' health agency, claiming it violated state and federal law by releasing the company's confidential Medicaid rebate information to two state senators.

Nov 18 2016

BRIEF-Pfizer announces pricing of tender offer for any and all of its 6.200 pct senior notes due March 15, 2019

* Pfizer announces pricing of tender offer for any and all of its 6.200 pct senior notes due March 15, 2019 Source text for Eikon: Further company coverage:

Nov 18 2016

Fitch Rates Pfizer's Notes Offering 'A+(exp)'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, November 15 (Fitch) Fitch Ratings has assigned an 'A+(EXP)' rating to Pfizer's senior unsecured notes offering. The net proceeds of the issuance will be used to fund the purchase of the company's 6.2% notes due March 15, 2019. The ratings apply to roughly $42.3 billion of debt outstanding at July 3, 2016. A full list of ratings follows at the end of this release. KEY RATING DRIVERS Little Leverage Flexibility: Despite Fitch

Nov 15 2016

Sanofi, GSK expect further price pressure, more M&A under Trump

LONDON Two of Europe's biggest drugmakers warned on Tuesday there would be no let up in pressure on U.S. medicine prices after last week's presidential election win for Republican Donald Trump, which sent pharmaceutical and biotech shares soaring.

Nov 15 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $111.96 --
Novartis AG (NOVN.S) CHF69.10 +0.35
Merck & Co., Inc. (MRK.N) $61.13 --
Roche Holding Ltd. (ROG.S) CHF222.40 +1.80
Roche Holding Ltd. (RO.S) CHF226.30 +1.70
Abbott Laboratories (ABT.N) $37.90 --
Bayer AG (BAYGn.DE) €87.96 +0.81
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.98 +0.68
AstraZeneca plc (AZN.L) 4,033.50p -21.50

Earnings vs. Estimates